These results show that, in lung cancer, GSK3α inhibition is beneficial for repressing cell viability and enhancing apoptosis, highlighting the need for a selective and specific GSK3α-inhibition-based therapy with chemical compounds. The gene discussed is GSK3A; the disease is lung carcinoma.